It is a measurement report about one specific batch, produced on a specific date by a specific method, and its value to you is entirely a function of how much of that context it discloses
On the cardiovascular side, the SUSTAIN-6 trial in 2016 was one of the first to report a significant reduction in major adverse cardiovascular events with semaglutide in adults with type 2 diabetes and high cardiovascular risk (Marso et al., NEJM, 2016)
doi: 10.1513/pats.200708-137mg, 10
HRT may be part of the conversation in eligible patients
Notably, Arg1 expression in MDSCs contributes to arginine depletion in the microenvironment, further inhibiting T-cell antitumor function and reducing their survival
[Advance in glutathione S-transferase kappa 1]